Tomato-Soy Juice Slashed 3 Inflammatory Cytokines in Adults With Obesity

Obesity drives a state of persistent, low-grade inflammation that quietly raises the risk of heart disease, type 2 diabetes, and cancer. Now, a small but rigorously designed crossover trial from researchers at Ohio State University and the USDA's Beltsville Human Nutrition Research Center suggests a specific tomato-soy juice can meaningfully dampen that inflammatory activity, and the mechanism turns out to involve the gut microbiome in ways the researchers did not fully anticipate.

Tomato-Soy Juice Reduces Three Key Inflammatory Cytokines

The published trial enrolled 12 adults with obesity (BMI between 30 and 45, ages 30 to 60) in a randomized crossover design. Each participant drank either the tomato-soy juice or a control juice daily for four weeks, then switched after a washout period. The control was not water or a placebo pill but a low-carotenoid yellow tomato juice, deliberately chosen to account for general tomato compounds. Blood and urine were collected before and after each intervention.

The tomato-soy juice significantly reduced three pro-inflammatory cytokines: IL-12p70, IL-5, and GM-CSF. TNF-alpha, a central driver of chronic inflammation linked to cardiovascular disease, diabetes, and cancer, trended downward and nearly reached statistical significance (p = 0.052). None of these reductions appeared during the control juice period. Plasma lycopene levels rose 2.48-fold after tomato-soy intake, reaching 1,298.4 nmol/L.

Why Whole-Food Combinations Outperform Single-Nutrient Approaches

The juice was formulated to deliver 54 mg of lycopene per day from tomatoes and 189.9 mg of soy isoflavones per day, both well above what a typical diet provides. The research team originally developed it in the context of prostate cancer research, then extended the work to pancreatitis and eventually to obesity-related inflammation after animal studies suggested the blend could reduce inflammatory activity.

Jessica Cooperstone, one of the lead researchers, was careful about the control design: "The hypothesis is that it's the lycopene from the tomatoes and the isoflavones from the soy that's inducing the effect, so we didn't want to have a control that's just water." Even so, the yellow tomato control juice altered some metabolic markers, suggesting other tomato compounds beyond lycopene remain biologically active. This points to a recurring finding in nutrition science: isolated nutrients rarely replicate the effects of the whole food matrix, and standardized dietary intervention trials are still working to untangle which components drive which outcomes.

Gut Microbiome Metabolism Amplifies the Soy Isoflavone Effect

The urine profiles from the trial revealed a striking metabolic story. Ethylphenol sulfate isomers, produced when gut bacteria break down genistein (one of the main soy isoflavones), increased 96- to 173-fold in urine after tomato-soy consumption. O-DMA glucuronides, derived from daidzein through gut microbial metabolism, were also significantly elevated. Some participants produced equol, a soy metabolite generated by specific gut bacteria that has been independently associated with anti-inflammatory activity.

This variation matters. Not everyone carries the microbial strains needed to convert soy isoflavones into their most potent downstream metabolites, which helps explain why individual responses to soy-based interventions have been inconsistent in prior research. The findings align with growing evidence that host-microbiome interactions shape the anti-inflammatory potential of dietary compounds in ways that serum nutrient levels alone cannot capture. Measuring urine metabolite profiles, as this study did, offers a more complete picture of what the body actually does with what it drinks.

Small Sample Size and Individual Variation Limit the Conclusions

With 12 participants, this trial is too small to establish population-level recommendations or to determine optimal dosing. The eligibility criteria were also restrictive: non-smokers, no recent antibiotic use, no specific supplements, and no certain health conditions. That careful selection strengthens internal validity but limits how broadly the results apply, particularly given how much individual microbiome composition varied within this cohort.

Cooperstone framed the ambition clearly: "The idea is, can we use food-based interventions to modulate inflammation? And can we test this in a rigorous way so that we can really see this is affecting inflammation?" The crossover design, the matched control juice, and the urine metabolomics all reflect that rigor. But inflammatory pathways are deeply interconnected, and reducing three cytokines in a four-week window in a dozen people is a foundation, not a conclusion.

What Comes Next for Tomato-Soy Juice Research

The researchers identified two directions that now warrant follow-up. First, larger trials with more diverse participants are needed to confirm whether the cytokine reductions hold at scale and to identify which microbiome profiles predict the strongest response. Second, mechanistic work is needed to clarify how lycopene, soy isoflavones, and the broader phytochemical matrix interact at the cellular level.

The juice's origins in prostate cancer research and its extension to pancreatitis and now obesity-related inflammation suggest a versatile functional food platform rather than a single-use intervention. For the roughly one in three adults in the United States who carry a BMI above 30, practical dietary tools that can reliably reduce inflammatory load without pharmaceuticals remain a meaningful gap. This trial does not fill that gap, but it offers a well-controlled signal that the tomato-soy combination is worth investigating at much larger scale.